Olivier Lozach

4.7k citations

87 papers · 3.8k indexed · h-index 37

Organic Chemistry top 0.5%
- Synthesis and Biological Evaluation 20
- Synthesis and Reactivity of Heterocycles 18
- Quinazolinone synthesis and applications 14
- Synthesis and Characterization of Heterocyclic Compounds 9
- Synthesis and biological activity 8
Toxicology top 0.5%
- Bioactive Compounds and Antitumor Agents 11
Pharmacology top 2%
Biotechnology top 5%
Molecular Biology top 5%
- Cancer therapeutics and mechanisms 19
Oncology
- Cancer-related Molecular Pathways 13

Co-authors: Laurent Meijer Yoan Ferandin Nirupma Singh Sham M. Sondhi Ashok Kumar Thierry Besson Sylvain Routier Karima Bettayeb
Cited by: Organic Chemistry Toxicology Pharmacology
Journals: Cancer Research (1 paper)International Journal of Molecular Sciences (1 paper)Journal of Medicinal Chemistry (14 papers)
Partner nations: France Germany Greece

In The Last Decade

Olivier Lozach

87 papers receiving 3.7k citations

Peers

Countries citing papers authored by Olivier Lozach

Since Specialization

Citations

This map shows the geographic impact of Olivier Lozach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Lozach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Lozach more than expected).

Fields of papers citing papers by Olivier Lozach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Lozach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Lozach. The network helps show where Olivier Lozach may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olivier Lozach, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olivier Lozach Line = papers co-authored together Olivier Lozach links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2- a ]pyridines derivatives as protein kinase inhibitors European Journal of Medicinal Chemistry ·Marie Lawson,Jordi Rodrigo,Blandine Baratte,Thomas Robert,Claire Delehouzé,Olivier Lozach,Sandrine Ruchaud,Stéphane Bach,Jean‐Daniel Brion,Mouâd Alami,Abdallah Hamzé	2016	26
2	Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. HAL (Le Centre pour la Communication Scientifique Directe) ·Aurélien Putey,Guy Fournet,Olivier Lozach,Lionel Perrin,Laurent Meijer,Benoı̂t Joseph	2014	11
3	Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors European Journal of Medicinal Chemistry ·Oussama Dehbi,Abdellatif Tikad,Stéphane Bourg,Pascal Bonnet,Olivier Lozach,Laurent Meijer,Mina Aadil,Mohammed Akssira,Gérald Guillaumet,Sylvain Routier	2014	35
4	Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling Bioorganic & Medicinal Chemistry Letters ·Luc Demange,Fatma Nait Abdellah,Olivier Lozach,Yoan Ferandin,Nohad Gresh,Laurent Meijer,Hervé Galons	2012	33
5	Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors European Journal of Medicinal Chemistry ·Amélie Bruel,Cédric Logé,Marie-Ludivine de Tauzia,Myriam Ravache,Rémy Le Guével,Christiane Guillouzo,Jean‐François Lohier,Jana Sopková‐de Oliveira Santos,Olivier Lozach,Laurent Meijer,Sandrine Ruchaud,Hélène Bénédetti,Jean‐Michel Robert	2012	30
6	Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide European Journal of Medicinal Chemistry ·Sébastien Deslandes,Delphine Lamoral‐Theys,Céline Frongia,Stefan Chassaing,Céline Bruyère,Olivier Lozach,Laurent Meijer,Bernard Ducommun,Róbert Kiss,Evelyne Delfourne	2012	25
7	Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues : A novel DYRK1A inhibitor class European Journal of Medicinal Chemistry ·Cléopatra Neagoie,Emeline Vedrenne,Frédéric Buron,Jean‐Yves Mérour,Sorin I. Roşca,Stéphane Bourg,Olivier Lozach,Laurent Meijer,Brigitte Baldeyrou,Amélie Lansiaux,Sylvain Routier	2012	80
8	Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors European Journal of Medicinal Chemistry ·Yvonnick Loidreau,Pascal Marchand,Carole Dubouilh‐Benard,Marie‐Renée Nourrisson,Muriel Duflos,Olivier Lozach,Nadège Loaëc,Laurent Meijer,Thierry Besson	2012	50
9	Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents European Journal of Medicinal Chemistry ·Paméla Kassis,Joanna Brzeszcz,Valérie Bénéteau,Olivier Lozach,Laurent Meijer,Rémi Le Guével,Christiane Guillouzo,K. Lewiński,Stéphane Bourg,Lionel Colliandre,Sylvain Routier,Jean‐Yves Mérour	2011	39
10	Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd0 catalysed reductive N-heteroannulation Organic & Biomolecular Chemistry ·Marie Laronze-Cochard,Fabien Cochard,Etienne Daras,Amélie Lansiaux,Bertrand Brassart,Enguerran Vanquelef,Elise Prost,Jean‐Marc Nuzillard,Brigitte Baldeyrou,Jean-François Goosens,Olivier Lozach,Laurent Meijer,Jean‐François Riou,Eric Henon,János Sápi	2010	14
11	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors European Journal of Medicinal Chemistry ·Mansour Debdab,Stéven Renault,Olivier Lozach,Laurent Meijer,Ludovic Paquin,François Carreaux,Jean Pierre Bazureau	2009	33
12	Rebeccamycin Derivatives as Dual DNA-Damaging Agents and Potent Checkpoint Kinase 1 Inhibitors Molecular Pharmacology ·Christelle Marminon,Fabrice Anizon,Pascale Moreau,Bruno Pfeiffer,Alain St. Pierre,Roy M. Golsteyn,Paul Peixoto,Marie‐Paule Hildebrand,Marie‐Hélène David‐Cordonnier,Olivier Lozach,Laurent Meijer,Michelle Prudhomme	2008	16
13	Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents Bioorganic & Medicinal Chemistry ·Ulrich Jacquemard,Nathalie Dias,Amélie Lansiaux,Christian Bailly,Cédric Logé,Jean‐Michel Robert,Olivier Lozach,Laurent Meijer,Jean‐Yves Mérour,Sylvain Routier	2008	53
14	Meriolins, a New Class of Cell Death–Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases Cancer Research ·Karima Bettayeb,Òscar M. Tirado,Séverine Marionneau‐Lambot,Yoan Ferandin,Olivier Lozach,Jonathan C. Morris,Silvia Mateo‐Lozano,Peter Drueckes,Christoph Schächtele,Michael H.G. Kubbutat,François Mouton‐Liger,Bernard Marquet,Benoı̂t Joseph,Aude Echalier,Jane Endicott,Vicente Notario,Laurent Meijer	2007	95
15	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3 Bioorganic & Medicinal Chemistry Letters ·Alexandra Testard,Cédric Logé,Benoît Léger,Jean‐Michel Robert,Olivier Lozach,Mélina Blairvacq,Laurent Meijer,Valérie Thiéry,Thierry Besson	2006	52
16	Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. Bioorganic & Medicinal Chemistry ·Dominique Laurent,Valérie Jullian,A.D.C. Parenty,Martine Knibiehler,Dominique Dorin,Sophie Schmitt,Olivier Lozach,Nicolas Lebouvier,Maryvonne Frostin,Frédéric Alby,Séverine Maurel,Christian Doerig,Laurent Meijer,Michel Sauvain	2006	60
17	Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff’s bases Bioorganic & Medicinal Chemistry ·Sham M. Sondhi,Nirupma Singh,Ashok Kumar,Olivier Lozach,Laurent Meijer	2006	296
18	A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors Bioorganic & Medicinal Chemistry ·Lucie Vandromme,Michel Legraverend,Sergio Kreimerman,Olivier Lozach,Laurent Meijer,David S. Grierson	2006	17
19	Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes Bioorganic & Medicinal Chemistry Letters ·B. VOIGT,Laurent Meijer,Olivier Lozach,Christoph Schächtele,Frank Totzke,Andreas Hilgeroth	2004	39
20	Synthesis and Target Identification of Hymenialdisine Analogs Chemistry & Biology ·Yongqin Wan,Wooyoung Hur,Charles Y. Cho,Yi Liu,Felicia Nathania Adrian,Olivier Lozach,Stéphane Bach,Thomas U. Mayer,Doriano Fabbro,Laurent Meijer,Nathanael S. Gray	2004	117

About Olivier Lozach

Olivier Lozach is a scholar working on Toxicology, Organic Chemistry and Molecular Biology, having authored 87 papers that have together received 3.8k indexed citations. Recurring topics across this work include Synthesis and Biological Evaluation (20 papers), Cancer therapeutics and mechanisms (19 papers), Synthesis and Reactivity of Heterocycles (18 papers), Quinazolinone synthesis and applications (14 papers), Cancer-related Molecular Pathways (13 papers), Bioactive Compounds and Antitumor Agents (11 papers), Synthesis and Characterization of Heterocyclic Compounds (9 papers) and Synthesis and biological activity (8 papers). The work is most often cited by research in Organic Chemistry (2.4k citations), Toxicology (239 citations) and Pharmacology (400 citations). Olivier Lozach has collaborated with scholars based in France, Germany and Greece. Frequent co-authors include Laurent Meijer, Yoan Ferandin, Nirupma Singh, Sham M. Sondhi, Ashok Kumar, Thierry Besson, Sylvain Routier, Karima Bettayeb, Valérie Thiéry and Jean‐Yves Mérour. Their work appears in journals such as Cancer Research, International Journal of Molecular Sciences and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact